Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

Following completion of the Phase 2, multicenter, randomized, active-controlled study of the
safety and tolerability of two formulations of CD101 compared to fluconazole for the
treatment of moderate to severe episodes of acute vulvovaginal candidiasis (NCT07299432),
subjects without a recurrence of VVC will be followed up to an additional 90 days +/- 14 days
to assess candida colonization and recurrence of VVC.

Inclusion Criteria:

- Enrollment in and completed the primary study through the Day 28 visit.

- Received at least one dose of study drug in the primary study

- Able to give written informed consent prior to completion of the primary study

Exclusion Criteria:

- Received systemic or topical vaginal non-study antifungal therapy at any time during
the primary study

- Diagnosed with bacterial vaginosis, trichomonas, gonorrhea, chlamydia, or active
herpes at any point during the primary study

- The Principal Investigator considers that the subject should not participate in the
study